Tumor immunotherapy using bone marrow-derived dendritic cells overexpressing Toll-like receptor adaptors

FEBS Letters

Volumn 581, Issue 18, 2007, Pages 3334-3340

  Akazawa, Takashi ^a   Shingai, Masashi ^b   Sasai, Miwa ^b   Ebihara, Takashi ^b   Inoue, Norimitsu ^a   Matsumoto, Misako ^a,b   Seya, Tsukasa ^a,b  

^a Osaka Medical Center for Cancer   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adoptive transfer; Densritic cell therapy; Lentivirus; MyD88; TRIF TICAM 1

Indexed keywords

ADAPTOR PROTEIN; ALPHA INTERFERON; CD86 ANTIGEN; INTERLEUKIN 12P40; INTERLEUKIN 6; LENTIVIRUS VECTOR; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL BASED GENE THERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DENDRITIC CELL; DRUG MECHANISM; FEMALE; GENE OVEREXPRESSION; MELANOMA; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ANIMALS; BONE MARROW CELLS; CELL LINE; DENDRITIC CELLS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNOTHERAPY; LENTIVIRUS; MICE; MYELOID CELLS; NEOPLASMS;

LENTIVIRUS;

EID: 34447274091     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2007.06.019     Document Type: Article

References (36)

1. Degli-Esposti M.A., and Smyth M.J. Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat. Rev. Immunol. 5 (2005) 112-124
2. Iwasaki A., and Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5 (2004) 987-995
3. Kawai T., Adachi O., Ogawa T., Takeda K., and Akira S. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 11 (1999) 115-122
4. Kawai T., Takeuchi O., Fujita T., Inoue J., Muhlradt P.F., Sato S., Hoshino K., and Akira S. Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J. Immunol. 167 (2001) 5887-5894
5. Oshiumi H., Matsumoto M., Funami K., Akazawa T., and Seya T. TICAM-1, an adapter molecule that participates in Toll-like receptor 3-mediated interferon-β induction. Nat. Immunol. 4 (2003) 161-167
6. Yamamoto M., Sato S., Hemmi H., Hoshino K., Kaisho T., Sanjo H., Takeuchi O., Sugiyama M., Okabe M., Takeda K., and Akira S. Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway. Science 301 (2003) 640-643
7. Akira S., and Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol. 4 (2004) 499-511
8. Oshiumi H., Sasai M., Shida K., Fujita T., Matsumoto M., and Seya T. TIR-containing adapter molecule (TICAM)-2, a bridging adapter recruiting to Toll-like receptor 4 TICAM-1 that induces interferon-β. J. Biol. Chem. 278 (2003) 49751-49762
9. Fitzgerald K.A., Rowe D.C., Barnes B.J., Caffrey D.R., Visintin A., Latz E., Monks B., Pitha P.M., and Golenbock D.T. LPS-TLR4 signaling to IRF-3/7 and NF-κB involves the toll adapters TRAM and TRIF. J. Exp. Med. 198 (2003) 1043-1055
10. Honda K., Ohba Y., Yanai H., Negishi H., Mizutani T., Takaoka A., Taya C., and Taniguchi T. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 434 (2005) 1035-1040
11. Honda K., and Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat. Rev. Immunol. 6 (2006) 644-658
12. Akazawa T., Masuda H., Saeki Y., Matsumoto M., Takeda K., Akira S., Azuma I., Toyoshima K., and Seya T. Adjuvant-mediated tumor regression and tumor-specific CTL induction are impaired in MyD88-deficient mice. Cancer Res. 64 (2004) 757-764
13. Akazawa T., Ebihara T., Okuno M., Okuda Y., Tsujimura K., Takahashi T., Ikawa M., Okabe M., Shingai M., Inoue N., Tanaka-Okamoto M., Ishizaki H., Miyoshi J., Matsumoto M., and Seya T. Antitumor NK activation induced by the Toll-like receptor3-TICAM-1 (TRIF) pathway in myeloid dendritic cells. Proc. Natl. Acad. Sci. USA 104 (2007) 252-257
14. Davila E., and Celis E. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. J. Immunol. 165 (2000) 539-547
15. Mellor A.L., Baban B., Chandler P.R., Manlapat A., Kahler D.J., and Munn D.H. Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J. Immunol. 175 (2005) 5601-5605
16. Tsuji S., Matsumoto M., Takeuchi O., Akira S., Azuma I., Hayashi A., Toyoshima K., and Seya T. Maturation of human dendritic cells by cell-wall skeleton of Mycobacterium bovis Bacillus Calmette-Guerin: involvement of Toll-like receptors. Infect. Immun. 68 (2000) 6883-6890
17. Prins R.M., Craft N., Bruhn K.W., Khan-Farooqi H., Koya R.C., Stripecke R., Miller J.F., and Liau L.M. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J. Immunol. 176 (2006) 157-164
18. Rechtsteiner G., Warger T., Osterloh P., Schild H., and Radsak M.P. Priming of CTL by transcutaneous peptide immunization with imiquimod. J. Immunol. 174 (2005) 2476-2480
19. Hornung V., Rothenfusser S., Britsch S., Krug A., Jahrsdorfer B., Giese T., Endres S., and Hartmann G. Quantitative expression of Toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol. 168 (2002) 4531-4537
20. Lauzon N.M., Mian F., MacKenzie R., and Ashkar A.A. The direct effects of Toll-like receptor ligands on human NK cell cytokine production and cytotoxicity. Cell Immunol. 241 (2006) 102-112
21. Bourke E., Bosisio D., Golay J., Polentarutti N., and Mantovani A. The Toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood 102 (2003) 956-963
22. Peng G., Guo Z., Kiniwa Y., Voo K.S., Peng W., Fu T., Wang D.Y., Li Y., Wang H.Y., and Wang R.F. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 309 (2005) 1380-1384
23. Tanaka H., Mori Y., Ishii H., and Akedo H. Enhancement of metastatic capacity of fibroblast-tumor cell interaction in mice. Cancer Res. 48 (1988) 1456-1459
24. Tanaka H., Tanigaki Y., Saeki Y., Ishibashi H., Matsuhisa T., Mori Y., Ogawa M., and Akedo H. Increased experimental pulmonary metastasis in pregnant mice. Int. J. Cancer 62 (1995) 314-318
25. Sasai M., Shingai M., Funami K., Yoneyama M., Fujita T., Matsumoto M., and Seya T. NAP1 (NAK-associated protein 1) participates in both the TLR3 and the cytoplasmic pathways in type I interferon induction. J. Immunol. 177 (2006) 8676-8683
26. Han K.J., Su X., Xu L.G., Bin L.H., Zhang J., and Shu H.B. Mechanisms of the TRIF-induced interferon-stimulated response element and NF-κB activation and apoptosis pathways. J. Biol. Chem. 279 (2004) 15652-15661
27. Inaba K., Inaba M., Naito M., and Steinman R.M. Dendritic cell progenitors phagocytose particulates, including bacillus Calmette-Guerin organisms, and sensitize mice to mycobacterial antigens in vivo. J. Exp. Med. 178 (1993) 479-488
28. Seya T., Akazawa T., Matsumoto M., Begum N.A., Azuma I., and Toyoshima K. Innate immune therapy for cancer: application of BCG-CWS and spirulina to patients with lung cancer. Anticancer Res. 23 (2002) 4369-4376
29. Killeen S.D., Wang J.H., Andrews E.J., and Redmond H.P. Exploitation of the Toll-like receptor system in cancer: a doubled-edged sword?. Brit. J. Cancer. 95 (2006) 247-252
30. Datta S.K., Redecke V., Prilliman K.R., Takabayashi K., Corr M., Tallant T., DiDonato J., Dziarski R., Akira S., Schoenberger S.P., and Raz E. A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J. Immunol. 170 (2003) 4102-4110
31. Schulz O., Diebold S.S., Chen M., Naslund T.I., Nolte M.A., Alexopoulou L., Azuma Y.T., Flavell R.A., Liljestrom P., and Reis e Sousa C. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433 (2005) 887-892
32. Funami K., Matsumoto M., Oshiumi H., Akazawa T., Yamamoto A., and Seya T. The cytoplasmic 'linker region' in Toll-like receptor 3 controls receptor localization and signaling. Int. Immunol. 16 (2004) 1143-1154
33. Dull T., Zufferey R., Kelly M., Mandel R.J., Nguyen M., Trono D., and Naldini L. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72 (1998) 8463-8471
34. Shimizu K., Thomas E.K., Giedlin M., and Mule J.J. Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein. Cancer Res. 61 (2001) 2618-2624
35. Schmidt T., Ziske C., Marten A., Endres S., Tiemann K., Schmitz V., Gorschluter M., Schneider C., Sauerbruch T., and Schmidt-Wolf I.G. Intratumoral immunization with tumor RNA-pulsed dendritic cells confers antitumor immunity in a C57BL/6 pancreatic murine tumor model. Cancer Res. 63 (2003) 8962-8967
36. Saika T., Satoh T., Kusaka N., Ebara S., Mouraviev V.B., Timme T.L., and Thompson T.C. Route of administration influences the antitumor effects of bone marrow-derived dendritic cells engineered to produce interleukin-12 in a metastatic mouse prostate cancer model. Cancer Gene Ther. 11 (2004) 317-324